Drug-diagnostic co-development in cancer

Pharmaceutical Medicine

Volumn 24, Issue 6, 2010, Pages 363-375

  Winther, Henrik ^a   Jørgensen, Jan Trøst ^b  

^a AGILENT TECHNOLOGIES   (United States)

^b Dx Rx Institute   (Denmark)

Author keywords

Cancer, treatment; Diagnostic Assays; Diagnostic Kits; Diagnostic Tests; European Medicines Agency; Food and Drug Administration; Immunoassay; Pharmaceutical industry; Research and development.

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; PANITUMUMAB; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CHINA; CLINICAL DEVELOPMENT PLAN; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG RESEARCH; EUROPE; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; NEOPLASM; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; UNITED STATES; VALIDATION PROCESS;

EID: 78649664462     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/bf03256837     Document Type: Review

References (50)

1. Jørgensen JT. From blockbuster medicine to personalized medicine. Per Med 2008; 5: 55-63
2. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201-4
3. Roche Corporate Communication. Prospects: more knowledge for medical science. Genes and health. 3rd ed. Basel: F Hoffmann-La Roche Ltd, 2007: 127-36
4. Sikora K. Personalized cancer therapy: key to the future. Pharmacogenomics 2004; 5: 225-8
5. Jørgensen JT, Winther H. The new era of personalized medicine: 10 years later. Per Med 2009; 6: 423-8
6. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-93
7. Hughes B. 2009 FDA drug approvals. Nat Rev Drug Discov 2010; 9: 89-92
8. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther 2007; 81: 164-9
9. Jørgensen JT. Are we approaching the post-blockbuster era? Pharmaco-diagnostics and rational drug development. Expert Rev Mol Diagn 2008; 8: 689-95
10. Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen-receptor interaction in target tissue. Arch Anat Microsc Morphol Exp 1967; 56: 547-69
11. Lerner HJ, Band PR, Israel L, et al. Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 1976; 60: 1431-5
12. Jørgensen JT, Winther H. The Hercep Test: from bench to bedside. In: Jørgensen JT, Winther H, editors. Molecular diagnostics: the key driver in personalized cancer medicine. Singapore: Pan Stanford Publishing, 2010
13. Jørgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies: a rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist 2007; 12: 397-405
14. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-16
15. Martin-Richard M, Munoz M, et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 2004; 66: 388-94
16. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa (TOP2A) amplifications and deletions as predictive markers in primary breast cancer patients randomized to cyclophosphamide, metho-trexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-90
17. Tanner MM, Isola J, Wiklund T, et al. Topoisomerase IIa gene amplification predicts favorable treatment response of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu amplified breast cancer: results from the randomized Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 1-9
18. Nielsen KV, Ejlertsen B, Møller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 2008; 47: 725-34
19. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101: 644-50
20. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004; 10: 6759-63
21. Evaluating the efficiency of targeted designs [Correction article]. Clin Cancer Res 2006; 12: 3229 [online]. Available from URL: http://clincancerres. aacr journals.org/content/12/10/3229.full [Accessed 2010 Oct 27]
22. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783-92
23. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol 2004; 31 Suppl. 3: 21-7
24. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72
26. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33
27. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 positive advanced gastric cancer [abstract LBA2409]. J Clin Oncol 2009; 27 Suppl.: 18s
28. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov 2006; 5: 463-9
29. Food and Drug Administration. Drug-diagnostic co-development concept paper: draft. 2005 Apr [online]. Available from URL: http://www.fda.gov/down loads/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/UCM116689. pdf [Accessed 2010 Oct 14]
30. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use ofmutation-targeted cancer therapies. Nat Biotechnol 2006; 24: 985-95
31. Companion diagnostics in personalized medicine and cancer therapy. TriMark Publications, LLC 2008
32. Rhodes A, Jasani B, Couturier J, et al. A formalin-fixed, paraffin-processed cell line standard for quality control ofimmunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002; 117: 81-9
33. Swanson J. Companion diagnostics take off [online]. Available from URL: http://www.genomeweb.com/dxpgx/companion-diagnostics-take [Accessed 2010 Oct 14]
34. Metcalfe TA. Development of novel IVD assays: a manufacturers perspective. Scand J Clin Lab Invest 2010; 70: 23-6
35. Scherf U, Becker R, Chan M, et al. Approval of novel biomarkers: FDA's perspective and major requests. ScandJClin Lab Invest Suppl 2010; 242: 96-102
36. Altman D, Bland JM. Diagnostic tests 2: predictive value. BMJ 1994; 309: 102
37. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027-34
38. Hoering A, LeBlance M, Crowley JJ. Randomized phase III trial designs for targeted agents. Clin Cancer Res 2008; 14: 4358-67
39. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52
40. State Food and Drug Administration [online]. Available from URL: http://www.sda.gov.cn [Accessed 2010 Oct 14]
41. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34
42. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and the benefit from cetuximab in advanced colorectal cancer. N Engl Med J 2008; 359: 1757-65
43. US Food and Drug Administration. 21 CFR Part 864. Medical devices: classification/reclassification of immunohistochemistry reagents and kits. Federal Register 1998; 63: 30132-42
44. Re: Comments on Development of Companion Diagnostics and the April 2005 Food and Drug Administration ('FDA') Drug Diagnostic Co-Development Concept Paper. 2009, December 9 PMC RX-DX Co-Development Letter To FDA [online]. Available from URL: http://www.personalizedmedicine coalition.org/sites/default/ files/files/FDA%20CoDevelopment%20FINAL %20Version%20PDF.pdf [Accessed 2010 Nov 19]
45. Hinman L, Spear B, Tsuchihashi Z, et al. Drugdiagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. Pharmacogenomics 2009; 10 (1): 127-36
46. Schilsky RL, Allen J, Benner J, et al. Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist 2010; 15 (5): 484-7
47. Gutman S, Kessler LG. TheUS Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006; 6: 565-71
48. Dati F. The new European directive on in vitro diagnostics. Clin Chem Lab Med 2003; 41: 1284-98
49. PricewaterhouseCoopers. Diagnostic 2009: moving towards personalized medicine [online]. Available from URL: http://www.pwc.com/us/en/health care/publications/diagnostics-2009-moving-towards-personalized-medicine. jhtml [Accessed 2010 Oct 14]
50. European Medicines Agency. Reflection paper on co-development of pharma-cogenomic biomarkers and Assays in the context of drug development. EMA/CHMP/641298/2008. Committee for Medicinal Products for Human Use (CHMP), 24 June 2010 [online]. Available from URL: http://www.emea.europa. eu/docs/en-GB/document-library/Scientific-guideline/2010/07/WC500094445. pdf [Accessed 2010 Oct 14]